COMMENTARY

Data Corroborate Harshness of Z2 Rule, Only Handful to Escape 2nd Consecutive Application

March 31, 2016
As the Ministry of Health, Labor and Welfare (MHLW) has released a list of new reimbursement prices for listed drugs, which will be effective April 1, we’ve seen a raft of long-listed products slapped with the so-called Z2 price cut…

To read the full story

COMMENTARY

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Takashi Ebisawa

On January 8, Japan’s biggest-ever outbound acquisition is expected to come to fruition, with London-listed Shire coming under the wing of Takeda Pharmaceutical. The Japanese major is paying £46 billion, or about 7 trillion yen, for the cash-and-stock deal, and…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…